---
title: "Immutep Limited (IMMP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IMMP.US.md"
symbol: "IMMP.US"
name: "Immutep Limited"
industry: "Biotechnology"
datetime: "2026-05-20T11:26:31.284Z"
locales:
  - [en](https://longbridge.com/en/quote/IMMP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IMMP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IMMP.US.md)
---

# Immutep Limited (IMMP.US)

## Company Overview

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.immutep.com](https://www.immutep.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.57)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 152 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 61.49% |  |
| Net Profit YoY | -90.24% |  |
| P/B Ratio | 1.12 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 74022873.40 |  |
| Revenue | 5185271.02 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -61.85% | E |
| Profit Margin | -1059.19% | E |
| Gross Margin | -673.61% | E |
| Revenue YoY | 61.49% | A |
| Net Profit YoY | -90.24% | E |
| Total Assets YoY | -13.11% | E |
| Net Assets YoY | -38.29% | E |
| Cash Flow Margin | 74.07% | C |
| OCF YoY | 61.49% | A |
| Turnover | 0.05 | E |
| Gearing Ratio | 32.81% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Immutep Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "61.49%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-90.24%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.12",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "74022873.40",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5185271.02",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-61.85%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1059.19%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-673.61%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "61.49%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-90.24%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-13.11%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-38.29%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "74.07%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "61.49%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.05",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "32.81%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.35 | 203/386 | - | - | - |
| PB | 1.12 | 106/386 | 4.29 | 2.64 | 2.19 |
| PS (TTM) | 14.28 | 183/386 | 112.22 | 79.09 | 72.27 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-02T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.50 |
| Highest Target | 1.00 |
| Lowest Target | 1.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IMMP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IMMP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IMMP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IMMP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**